haemophilia B

Showing 8 posts of 8 posts found.


NHS Scotland gives green light to funding haemophilia A drug Hemlibra

December 18, 2019
Research and Development NHS, haemophilia, haemophilia B, haemophilia a, nhs scotland

NHS Scotland has commissioned Hemlibra (emicizumab), by Chungai Pharma UK Ltd and Roche Products Ltd, to treat people with congenital …


Irish haemophilia A patients to get continued access to Sobi’s extended half-life factor replacement therapy

December 17, 2019
Manufacturing and Production haemophilia, haemophilia B, haemophilia a

The Republic of Ireland’s Haemophilia Product Selection and Monitoring Advisory Board (HPSMAB) and Sobi United Kingdom and Republic of Ireland, …

Pfizer and Spark Therapeutics granted FDA breakthrough designation for haemophilia drug

July 22, 2016
Medical Communications, Research and Development FDA, Pfizer, Spark Therapeutics, haemophilia B, spk-9001

Pfizer and Spark Therapeutics have announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation …

Pfizer and Spark Therapeutics present early data on bio-engineered haemophilia drug

May 23, 2016
Research and Development, Sales and Marketing Pfizer, Spark Therapeutics, gene therapy, haemophilia B

Pfizer (NYSE: PFE) and Spark Therapeutics (NASDAQ: ONCE) have announced that they will present data showing encouraging signs in their …


EU approves Idelvion for haemophilia B treatment

May 13, 2016
Medical Communications, Research and Development CSL, EU, Idelvion, approval, haemophilia B

The European Commission has approved Idelvion, coagulation Factor IX (recombinant) for the treatment and prophylaxis of bleeding in patients with …


Sobi, Biogen’s haemophilia B therapy gets European approval

May 13, 2016
Medical Communications, Research and Development, Sales and Marketing Biogen, haemophilia B, orphan designation, regulation, sobi

Sobi (STO: SOBI) and Biogen (Nasdaq: BIIB) on Friday said the European Commission has approved their drug to treat haemophilia B. The …


Albumedix technology extends dosing interval in Behring haemophilia B drug

March 22, 2016
Manufacturing and Production, Research and Development Albumedix, GSK, Idelvion, Novozymes, VELTIS, haemophilia B

Novozymes subsidiary Albumedix has scored another big pharma tie-up for its albumin-based half-life extension technology VELTIS, which this time is …

Late-stage Pfizer drug study shows significant reduction in haemophilia B bleeding

March 9, 2016
Research and Development BeneFIX, Pfizer, haemophilia B

Pfizer on Wednesday said late-stage trials for its drug candidate to treat haemophilia B showed prophylactic use resulted in significant reduction …

Latest content